UBS maintains sell rating for DocMorris with price target of 25 francs

UBS has given DocMorris a "Sell" rating with a price target of 25 francs.

According to analyst Olivier Calvet, recent evaluation shows trends in app usage and downloads, as well as pricing strategies in the German online pharmacy market.

The data suggests that Redcare is increasing its price investments, while DocMorris is decreasing such measures.

Furthermore, app activity among Swiss users is reportedly declining, indicating that DocMorris is falling behind Redcare.

This analysis is based on regular figures on the performance of online pharmacies, highlighting the competitive landscape in the sector.

Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings